NASDAQ: BCABBioatla Inc Stock
$4.19+0.10 (+2.44%)
Updated Jul 2, 2026
BCAB Price
$4.19
Fair Value Price
-$0.58
Market Cap
$6.94M
52 Week Low
$3.12
52 Week High
$71.50
P/E
-0.1x
P/B
-0.19x
P/S
6.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.00M
Earnings
-$50.62M
Gross Margin
100%
Operating Margin
-2,530.85%
Profit Margin
-2,530.8%
Debt to Equity
-1.23
Operating Cash Flow
-$37M
Beta
1.76
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BCAB Overview
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BCAB's potential to beat the market
- BCAB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BCAB
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important BCAB news, forecast changes, insider trades & much more!
BCAB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BCAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCAB ($4.19) is overvalued by 827.58% relative to our estimate of its Fair Value price of -$0.58 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCAB ($4.19) is not significantly undervalued (827.58%) relative to our estimate of its Fair Value price of -$0.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCAB due diligence checks available for Premium users.
Valuation
BCAB fair value
Fair Value of BCAB stock based on Discounted Cash Flow (DCF)
Price
$4.19
Fair Value
-$0.58
Undervalued by
827.58%
BCAB ($4.19) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCAB ($4.19) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.1x
Industry
17.59x
Market
8.54x
BCAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.19x
Industry
5.6x
BCAB's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.3M
Profit Margin
0%
BCAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BCAB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.6M
Liabilities
$45.9M
Debt to equity
-1.23
BCAB's short-term liabilities ($20.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCAB's long-term liabilities ($25.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCAB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.3M
Investing
$0.0
Financing
$110.0k
BCAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCAB vs Biotech Stocks
Bioatla Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.